David Gauden, Blue Earth Therapeutics CEO
October 30, 2024 08:00 AM EDT
Financing
Startups

Blue Earth Ther­a­peu­tics snags $76M for both al­pha and be­ta ra­dio­ther­a­pies

Kyle LaHucik

Senior Reporter

The ra­dio­phar­ma field con­tin­ues to buzz with pri­vate fi­nanc­ings and more clin­i­cal-stage pro­grams.

The lat­est is Ox­ford, UK-based Blue Earth Ther­a­peu­tics, which un­veiled a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times